Olmesartan Medoxomilo Ciclum (Olmesartan Medoxomil)

Olmesartan medoxil is an ARB that lowers blood pressure by blocking the renin‑angiotensin system.

• Hypertension: helps achieve target blood pressure and reduces cardiovascular risk.
• Heart failure: used as part of combination therapy to improve symptoms and outcomes.
• Diabetic nephropathy: slows progression of kidney damage associated with diabetes.

• Olmesartan medoxil is a selective antagonist of the angiotensin II type 1 (AT1) receptor. By blocking AT1, it prevents angiotensin II‑mediated vasoconstriction, aldosterone release, and sympathetic activation, leading to vasodilation, reduced sodium and water retention, and lowered systemic blood pressure.

Olmesartan medoxil may cause a range of adverse reactions.

Common Side Effects

• Dizziness
• Headache
• Fatigue
• Nasal congestion
• Diarrhea
• Upper respiratory infection

Serious or Rare Side Effects

• Angio‑edema
• Hyperkalemia
• Acute kidney injury
• Severe hypotension
• Liver enzyme elevation
• Myocardial infarction (rare)

When prescribing olmesartan medoxil, clinicians should consider several safety aspects.

• Renal function: assess baseline kidney function and monitor periodically.
• Electrolytes: check serum potassium, especially if combined with potassium‑sparing agents.
• Pregnancy: contraindicated in the second and third trimesters.
• Elderly patients: start at lower dose and monitor for hypotension.
• Drug interactions: review concomitant medications for additive blood‑pressure effects.
• Store at ambient temperature: keep in original packaging, protect from moisture and light.

Olmesartan medoxil can interact with several medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid)

• Aliskiren: combined use in diabetic patients may increase risk of renal impairment.
• Potassium‑rich supplements: may cause dangerous hyper‑kalaemia.

Moderate Interactions (Monitor Closely)

• NSAIDs: may blunt antihypertensive effect and affect renal function.
• Diuretics: may enhance hypotensive response.
• Lithium: may increase lithium levels.
• ACE inhibitors: concurrent use can increase risk of angio‑edema.
• CYP450 inducers: may reduce plasma concentration of olmeset.